[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642202":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":51,"responsibleParty":76,"collaborators":49,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":49,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":54,"whyStopped":49,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University of Oklahoma","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active near-infrared light therapy","ACTIVE_COMPARATOR","Participants in this arm will receive 20-minute active transcranial photobiomodulation sessions six times a week for 12 weeks during their participation in the study. The intervention will be administered using an active Vielight Neuro RX-Duo, a research version of a commercially available light therapy device categorized as a wellness product with non-significant risk. During these sessions, biologically effective near-infrared light will be administered.",[13],"Device: Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham near-infrared light therapy","SHAM_COMPARATOR","Participants in this arm will receive 20-minute sham transcranial photobiomodulation sessions six times a week for 12 weeks during their participation in the study. The intervention will be administered using a sham Vielight Neuro RX-Duo, a research version of a commercially available light therapy device categorized as a wellness product with non-significant risk. During these sessions, biologically effective near-infrared light will not be administered.",[19],"Device: Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation","The active Vielight Neuro RX-Duo devices (© Vielight Inc.) will be used to transmit pulsed near-infrared (NIR) energy through the cranium. The device emits NIR photons at an 810-nm wavelength, generating \\~250 mW\u002Fcm² of pulsed NIR power modulated at 10 and 40 Hz frequencies (Alpha and Gamma modes). The six NIR light sources are positioned along the midline over the frontal, parietal, and occipital cortices, bilaterally over the temporal cortices, and intranasally. Because of their portable design, Vielight Neuro RX-Duo instruments can be used in the laboratory, at the bedside, or in the participant's home.\n\nActive photobiomodulation sessions will last 20 minutes and will be administered in a laboratory, home, or office setting, depending on participant preference. TPBM will be delivered once per day, six times per week, for 12 weeks. Participants will complete an adverse-events questionnaire after each session.",[9],[27,28],"tPBM","near-infrared light therapy",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation","Sham Vielight Neuro RX-Duo devices (© Vielight Inc.) will be used. These devices are identical in appearance to the active devices; however, they do not emit near-infrared (NIR) light at an 810-nm wavelength. The six light sources are positioned along the midline over the frontal, parietal, and occipital cortices; bilaterally over the temporal cortices; and intranasally. Because of their portable design, Vielight Neuro RX-Duo instruments can be used in the laboratory, at the bedside, or in the participant's home.\n\nSham photobiomodulation sessions will last 20 minutes and will be administered in a laboratory, home, or office setting, depending on participant preference. TPBM will be delivered once per day, six times per week, for 12 weeks. Participants will complete an adverse-events questionnaire after each session.",[15],[27,28],[35],{"name":36,"affiliation":37,"role":38},"Peter Mukli, MD, PhD","Department of Neurosurgery, University of Oklahoma Health Campus, Oklahoma, USA","PRINCIPAL_INVESTIGATOR",[40,46],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Peter Mukli","CONTACT","+1 (405) 271-8001","37745","peter-mukli@ou.edu",{"name":47,"role":42,"phone":48,"phoneExt":49,"email":50},"Leslie Guthery","+1 (405) 271-4113",null,"leslie-guthery@ou.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"University of Oklahoma Health Campus","RECRUITING","Oklahoma City","Oklahoma","73104","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-97.51643,35.46756,{"lat":64,"lon":63},[67,70,73,74],{"name":68,"role":42,"phone":69,"phoneExt":49,"email":50},"Leslie Guthery, MS","405-271-4113",{"name":71,"role":42,"phone":72,"phoneExt":49,"email":49},"OUHSC Director Office of H.R.P.P.","+1 (405) 271 2045",{"name":36,"role":38,"phone":49,"phoneExt":49,"email":49},{"name":75,"role":38,"phone":49,"phoneExt":49,"email":49},"Calin Prodan, MD",{"type":77,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100642202","using-light-therapy-for-mild-cognitive-impairment-100642202",false,"NCT07651787","Using Light Therapy for Mild Cognitive Impairment","Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment","LTMC","Inclusion Criteria:\n\n* Age: 55-95 years of age\n* Clinical Dementia Rating (CDR) equal to 0.5 and\u002For Montreal Cognitive Assessment (MoCA) \\\u003C26 and ≥19\n* Adequate hearing and visual acuity to participate in the examinations\n* English speaker\n* Presence of cerebrovascular pathology confirmed by structural brain imaging method\n\nExclusion Criteria:\n\n* Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer\n* Cerebrovascular accident other than TIA within 60 days prior to Visit 0\n* Diagnosis of amyloid angiopathy\n* Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse\n* Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia\n* Patients currently using commercial brain stimulation \u002F neuromodulation device as part of a research study\n* Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin\n* Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\\>160\u002F100 mmHg)\n* Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol\n* Severe sensory deficits interfering with the testing","ALL","55 Years","95 Years",{"count":90,"type":91},40,"ESTIMATED","INTERVENTIONAL",[94],"NA","The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are:\n\n* Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks?\n* Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage?\n* Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.\n\nParticipants will:\n\n* Receive a 20-minute-long active tPBM or sham stimulation session once per day, 6 times per week, for 12 weeks.\n* Complete questionnaires and an iPad-based cognitive testing protocol.\n* Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Dynamic analysis of the vessels in the eye will also be performed based on eligibility. Transcranial Doppler (TCD) flowmetry is optionally performed.\n* Provide blood samples to test for biomarkers of inflammation, oxidative stress, and brain cell damage.",[97,98],"Mild Cognitive Impairment (MCI)","Amyloid Pathology",[100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122],"Cognition","Neurovascular Coupling Mechanism and Cognitive Function","Neurovascular Control","Brain Aging","Brain Activity","Mild Congitive Impairment (MCI)","Amyloid","Transcranial photobiomodulation","Near-infrared spectroscopy","Cerebral hemodynamics","Near-infrared light therapy","NIH Toolbox Cognition Battery","Electroencephalography","Amyloid-positive mild cognitive impairment","Amyloid-negative mild cognitive impairment","Extracellular vesicles","Neuroinflammation","Proinflammatory cytokines","Home-based neuromodulation","Non-invasive brain stimulation","Sham-controlled clinical trial","Randomized clinical trial","photobiomodulation therapy","2026-06-10",{"date":125,"type":126},"2026-06-16","ACTUAL",{"date":128,"type":126},"2025-10-01",{"date":130,"type":91},"2026-12-31",{"name":5,"class":6},1]